Citigroup Upgrades Sanofi (NASDAQ:SNY) to Strong-Buy

Citigroup upgraded shares of Sanofi (NASDAQ:SNY) to a strong-buy rating in a research note published on Tuesday, Zacks.com reports.

A number of other equities analysts have also weighed in on SNY. StockNews.com lowered Sanofi from a strong-buy rating to a buy rating in a research note on Wednesday, September 11th. Argus upped their target price on Sanofi from $55.00 to $60.00 and gave the stock a buy rating in a research note on Friday, July 26th. Three analysts have rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $57.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $57.63 on Tuesday. The firm has a market capitalization of $145.96 billion, a P/E ratio of 28.96, a P/E/G ratio of 1.62 and a beta of 0.60. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock’s 50-day simple moving average is $54.34 and its two-hundred day simple moving average is $50.48. Sanofi has a twelve month low of $42.63 and a twelve month high of $58.97.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The business had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.95 EPS. As a group, equities analysts anticipate that Sanofi will post 4.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Sanofi

Several institutional investors have recently modified their holdings of the company. Boston Partners boosted its holdings in Sanofi by 0.3% during the 1st quarter. Boston Partners now owns 13,066,403 shares of the company’s stock valued at $635,280,000 after acquiring an additional 33,657 shares during the period. Bank of New York Mellon Corp boosted its holdings in Sanofi by 19.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the period. Barrow Hanley Mewhinney & Strauss LLC boosted its holdings in Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after acquiring an additional 3,164,092 shares during the period. Mondrian Investment Partners LTD boosted its holdings in Sanofi by 43.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 3,951,089 shares of the company’s stock valued at $192,023,000 after acquiring an additional 1,190,141 shares during the period. Finally, Envestnet Asset Management Inc. lifted its holdings in Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock worth $157,803,000 after buying an additional 246,224 shares during the period. 10.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.